

1 **Title:**

2 **Trends in neural tube defects in Scotland 2000-2021 prior to the introduction of**  
3 **mandatory folic acid fortification of non-wholemeal wheat flour: a population-based**  
4 **study.**

5

6 **Author list:**

7 Amir Kirolos<sup>1</sup>, Rute Vieira<sup>1,2</sup>, Clara Calvert<sup>1,3</sup>, Emily Griffiths<sup>1</sup>, Rachael Wood<sup>1,3</sup>

8 1. Public Health Scotland, Edinburgh, Scotland, UK.

9 2. Institute of Applied Health Sciences, School of Medicine, Medical Sciences and  
10 Nutrition, The University of Aberdeen, Aberdeen, Scotland.

11 3. Usher Institute, University of Edinburgh, Edinburgh, Scotland, UK

12

13 Corresponding author: Professor Rachael Wood ([rachael.wood@phs.scot](mailto:rachael.wood@phs.scot))

14

15 **Abstract:**

16 **Objective:** To describe the total birth prevalence of neural tube defects (NTDs) in Scotland  
17 2000-2021.

18 **Design:** National, population-based study.

19 **Setting:** Scotland, UK.

20 **Participants:** Babies with an NTD and pregnancy outcome of live birth, stillbirth ( $\geq 20$  weeks  
21 gestation), or termination of pregnancy (any gestation), as recorded in the Scottish Linked  
22 Congenital Condition Dataset.

23 **Exposures:** Year, maternal age group, maternal area-level deprivation quintile.

24 **Main outcome measures:** Total birth prevalence of all NTDs and, separately, anencephaly  
25 and spina bifida (per 10,000 total births). The association between exposures and outcomes  
26 was investigated using Poisson regression.

27 **Results:** In Scotland 2000-2021, there were 1,178 babies with a recorded NTD (436  
28 anencephaly, 577 spina bifida) and 1,203,491 total births. Total birth prevalence of NTDs was  
29 9.8 [95% CI 9.2, 10.4] per 10,000 total births. Prevalence was lower among babies to  
30 mothers aged 30-39 years (compared to younger or older) and those from less (compared to  
31 more) deprived areas. There was no evidence of change over the study period in prevalence  
32 of NTDs (prevalence rate ratio [PRR] 1.01 [95% CI 0.997, 1.02]  $p=0.16$ ), or spina bifida (PRR  
33 0.99 [95% CI 0.98, 1.01]  $p=0.35$ ). The prevalence of anencephaly showed no change 2000-  
34 2012, then increased 2013-2021 (PRR 1.12 [95% CI 1.06, 1.19]  $p<0.001$ ).

35 **Conclusions:** Observed trends in anencephaly likely reflect increasing detection in early  
36 pregnancy. Current strategies are failing to equitably reduce NTDs in Scotland. Monitoring of  
37 future trends is needed to assess the impact of mandatory folic acid fortification.

38

39 **Summary:**

40 **What is already known on this topic**

- 41 - Recommendations for voluntary fortification of some foods, and for pre-conception  
42 daily supplements of folic acid, have been in place since the 1980s and 1990s  
43 respectively to support prevention of neural tube defects (NTDs).  
44 - Most women do not take folic acid supplements before conception, and uptake is  
45 particularly low in younger mothers and those from poorer socioeconomic  
46 backgrounds.  
47 - Legislation to mandate the fortification of non-wholemeal wheat flour with folic acid  
48 was introduced in November 2024. This provides an opportunity to improve the  
49 equitable prevention of NTDs.

50 **What this study adds**

- 51 - There is no evidence that the total birth prevalence of NTDs in Scotland changed  
52 2000-2021. Prevalence was lowest among mothers in the 30-39 year age group, and  
53 those from less deprived areas.  
54 - There is no evidence that the total birth prevalence of spina bifida in Scotland  
55 changed 2000-2021, however the prevalence of anencephaly increased 2013-2021,  
56 likely reflecting increasing early antenatal detection of this condition through  
57 ultrasound scans.

58 **How this study might affect research, practice, or policy**

- 59        - This study provides baseline information for the period before the introduction of  
60            mandatory fortification. It will be used to support the evaluation of mandatory  
61            fortification, and hence guide future policy development.

62 **Introduction:**

63 Neural tube defects (NTDs) (comprising anencephaly, spina bifida, and, least commonly,  
64 encephalocele) are congenital conditions arising due to incomplete closure of the neural  
65 tube during early fetal development(1). Pregnancies affected by an NTD are at increased risk  
66 of miscarriage or stillbirth. Babies born with spina bifida have lifelong disabilities that can  
67 include paraplegia, bladder and bowel dysfunction, hydrocephalus, and learning disabilities.  
68 Anencephaly is incompatible with long term survival. The chance of having an affected  
69 pregnancy increases with decreasing maternal levels of folate (vitamin B9) and there is well  
70 established evidence that taking pre-conception supplements of folic acid (a synthetic form  
71 of folate) reduces the risk of having an affected pregnancy(2-4).

72 There is evidence that the total birth prevalence (hereafter 'prevalence' for brevity) of NTDs  
73 fell in the UK between the 1970s and 1990s then stabilised, linked to dietary improvements  
74 and, from the mid-1980s onwards, the voluntary fortification of some breakfast cereals and  
75 bread with folic acid(5). Daily folic acid supplements have also been recommended for  
76 women who are planning, and in the first trimester of, pregnancy since 1992(6). However, a  
77 study in England in 1999-2012 found only a third reported taking supplements before  
78 conception(7). The uptake of supplements, and folate status, vary markedly by maternal  
79 sociodemographic factors(8,9).

80 Mandatory folic acid fortification of various staple foods introduced in other countries has  
81 been associated with a reduction in the prevalence of NTDs(10). Legislation to mandate the  
82 fortification of non-wholemeal wheat flour (and hence all products containing this flour) in  
83 the UK at a level of 250mcg per 100g was introduced in November 2024, for implementation  
84 by end 2026(11). Recommendations on daily folic acid supplements (and the possibility of

85 additional voluntary fortification) remain unchanged. Modelling estimates this will lead to a  
86 15-22% reduction in the prevalence of NTDs(12).

87 We aimed to examine secular trends in the prevalence of NTDs in Scotland 2000-2021.  
88 Establishing these pre-implementation trends will support evaluation of the impact of  
89 mandatory fortification and guide future policy decisions.

90

## 91 **Methods:**

92 Our study protocol is available at [https://publichealthscotland.scot/publications/trends-in-](https://publichealthscotland.scot/publications/trends-in-neural-tube-defects-protocol/)  
93 [neural-tube-defects-protocol/](https://publichealthscotland.scot/publications/trends-in-neural-tube-defects-protocol/). We followed STROBE reporting guidelines(13).

## 94 **Data Sources**

### 95 *Scottish Linked Congenital Condition Dataset (SLiCCD)*

96 SLiCCD includes all babies from pregnancies ending in Scotland 2000-2021 that were  
97 recorded as having a major congenital condition on a relevant source dataset(14,15). Major  
98 congenital conditions are defined as structural or chromosomal conditions meeting  
99 EUROCAT inclusion criteria(16). Babies are included in SLiCCD if the pregnancy ends in a live  
100 birth (any gestation, baby diagnosed before their first birthday), stillbirth ( $\geq 20$  weeks  
101 gestation), or termination of pregnancy (any gestation). SLiCCD is derived from the following  
102 national datasets: statutory live birth, stillbirth ( $\geq 24$  weeks gestation), and infant ( $< 1$  year)  
103 death registration records; statutory termination of pregnancy notifications; hospital  
104 maternity, neonatal, and paediatric ( $< 1$  year) inpatient discharge records; and MBRRACE-UK  
105 perinatal mortality surveillance records(17). Diagnostic codes on these source records are  
106 examined to identify records indicating a relevant condition. All records relating to an

107 individual baby are then reconciled to provide personal identifiers; pregnancy end date and  
108 outcome; sociodemographic variables including maternal age, maternal deprivation category  
109 (Scottish Index of Multiple Deprivation (SIMD) quintile based on postcode of residence at  
110 the end of pregnancy(18)), and infant sex; and the diagnostic codes indicating the congenital  
111 condition(s) present(19). Each baby is allocated to one or more EUROCAT-defined condition  
112 group (e.g., Nervous system conditions), level 1 subgroup (e.g., Neural tube defects), and  
113 level 2 subgroup (e.g., Anencephaly, Encephalocele, Spina bifida) based on their diagnostic  
114 codes. Babies with only non-specific codes available may be assigned to no groups, or to a  
115 group but none of its subgroups. If a baby with an NTD has an underlying genetic condition,  
116 that is flagged by also allocating them to the Genetic conditions group.

117 *Congenital Conditions and Rare Diseases Registration and Information Service for Scotland*  
118 *(CARDRISS) register*

119 The CARDRISS register is a new, validated register of all babies with a major congenital  
120 condition from pregnancies ending in Scotland 2021 onwards(20). It has the same inclusion  
121 criteria as SLiCCD and uses the same source datasets, though CARDRISS uses a broader list of  
122 codes to identify babies that may have a registerable condition. Trained registration staff  
123 then access local clinical records to confirm whether a provisionally registered baby meets  
124 inclusion criteria and, if so, complete their registration record, including de novo coding of all  
125 congenital conditions present.

126 *National Records of Scotland (NRS) live and stillbirths*

127 Aggregate data on the number of registered live births (any gestation) and stillbirths ( $\geq 24$   
128 weeks gestation) were used as denominators to allow calculation of the total birth

129 prevalence of NTDs. Aggregate data was obtained for each year broken down by maternal  
130 age group, maternal deprivation quintile, and infant sex.

### 131 **Statistical analysis**

132 Statistical analyses were conducted using R v4.1.2. Code is available at

133 <https://github.com/Public-Health-Scotland/trends-in-ntds-public>.

#### 134 *Number and total birth prevalence of NTDs*

135 We used SLiCCD to report the total number of babies with an NTD from pregnancies ending  
136 2000-2021 inclusive. We examined distribution by pregnancy outcome (live birth, stillbirth  
137 [≥20 weeks], termination of pregnancy). In line with EUROCAT guidelines, we calculated the  
138 total birth prevalence ('prevalence') of NTDs per 10,000 total (registered live and still [≥24  
139 weeks]) births overall, and by maternal age group and deprivation. Total birth prevalence is  
140 the accepted proxy estimate of incidence of congenital conditions(21). We also calculated  
141 the live birth prevalence of NTDs as the number of live born babies with an NTD per 10,000  
142 live births, overall and by infant sex (which is only reliably recorded for live births).

#### 143 *Time trend analysis*

144 We calculated the unadjusted prevalence of NTDs for each year with 95% confidence  
145 intervals (CI) using Poisson (evidence of equidispersion of data) or Conway-Maxwell-Poisson  
146 (COM-Poisson, evidence of over/underdispersion) regression models, fitted with year as the  
147 exposure. We fitted two models: a) assuming a linear trend over time and b) using restricted  
148 cubic splines assuming a non-linear trend over time; and selected the best-fitting model  
149 using the Akaike Information Criteria (AIC).



150 If the model with a linear trend was chosen, we reported the unadjusted prevalence rate  
151 ratio (uPRR) for year (PRR for year estimates the average annual percentage change in  
152 prevalence) for the whole study period. If the model with a non-linear trend was chosen, we  
153 used visual inspection of plots to divide the study period into sequential sub-periods, each  
154 with a linear trend. We then used piecewise regression models to calculate the uPRRs for  
155 year for each sub-period.

### 156 *Sociodemographic factors*

157 We used Poisson or COM-Poisson models to calculate uPRRs for the association between  
158 prevalence of NTDs and, separately, maternal age and deprivation. To provide adjusted PRRs  
159 (aPRRs) for these associations, we extended each model to include year as an exposure  
160 (Models 1 and 2). Finally, we fitted a model including maternal age, deprivation, and year as  
161 exposures (Model 3). Models assumed a linear or non-linear time trend as per findings in  
162 the time trend analyses. Babies with missing data for maternal age and deprivation were  
163 dropped from models including these variables.

164 If the time trend analysis showed a linear trend, models 1-3 were also used to provide the  
165 aPRR for year adjusted for maternal age, deprivation, and both factors respectively. If the  
166 time trend analysis showed a non-linear trend, aPRRs for year for each sub-period were not  
167 provided as the relationship between the sociodemographic factors and prevalence may  
168 vary across the sub-periods making the aPRRs difficult to interpret.

169 All analyses were repeated for the two most common sub-types of NTDs (anencephaly and  
170 spina bifida) and for NTDs without an associated genetic condition (as NTDs in babies with  
171 an associated genetic condition are less preventable by folate supplementation(22)).

172 *Validation of SLiCCD against CARDRISS*

173 We used data from the crossover period in 2021 to calculate the positive predictive value  
174 (PPV) and sensitivity of recording of babies with NTDs in SLiCCD compared to CARDRISS(20).  
175 PPV was the percentage of babies with an NTD included in SLiCCD that were also recorded  
176 as having an NTD in CARDRISS. Sensitivity was calculated as the percentage of babies with an  
177 NTD included in CARDRISS that were also recorded as having an NTD in SLiCCD. Analyses  
178 were repeated for anencephaly, spina bifida, and NTDs without an associated genetic  
179 condition.

180 *Power to detect a 20% reduction in the prevalence of NTDs*

181 As CARDRISS rather than SLiCCD will be used for prospective evaluation of the impact of  
182 mandatory fortification, we calculated the prevalence of NTDs based on CARDRISS data for  
183 2021. We assumed this prevalence and number of births would be the same for 2022-2024  
184 to give us our pre-implementation data (CARDRISS data for 2022 onwards is not yet  
185 available). We then calculated the power we would have to detect a 20% reduction in the  
186 prevalence of NTDs(12,23) based on the cumulative number of births that would occur in the  
187 10 years following full implementation of mandatory fortification. For this power calculation,  
188 we assumed the annual number of births for these 10 years would remain the same as 2021  
189 throughout, and that the 20% reduction occurred in the first year and then did not change.

190 **Patient and Public involvement**

191 We consulted with stakeholders including Spina Bifida Hydrocephalus Scotland to inform  
192 study design and interpretation.

193

194 **Results:**

195 **Number and total birth prevalence of NTDs**

196 A total of 1,178 babies with an NTD and pregnancy end date 2000-2021 were included in  
197 SLiCCD, of which 436 (37%) had anencephaly, 165 (14%) encephalocele, and 577 (49%) spina  
198 bifida (Table 1). There were 1,203,491 total births in 2000-2021, giving a prevalence of NTDs  
199 of 9.8 [95% CI 9.2, 10.4] per 10,000 total births. Prevalence per 10,000 total births was 3.6  
200 [95% CI 3.3, 4.0] for anencephaly, 1.4 [95% CI 1.2, 1.6] for encephalocele, and 4.8 [95%CI  
201 4.4, 5.2] for spina bifida. Of the 1,178 babies with an NTD, 1,118 (95%) did not have an  
202 associated genetic condition (Supplementary Table 1). Overall, 35% (414) of the 1,178 babies  
203 with an NTD were live births. Pregnancy outcomes varied across the subtypes of NTD, with  
204 8% (33) of babies with anencephaly and 53% (307) with spina bifida being live births.

205 The prevalence of NTDs was lower in maternal age groups 30-34 years and 35-39 years (8.6  
206 [95% CI 7.7, 9.6] and 7.5 [95% CI 6.3, 8.7] per 10,000 total births respectively) compared to  
207 younger and older age groups (Table 2). Similar patterns were observed for anencephaly,  
208 spina bifida, and NTDs without an associated genetic condition (Supplementary Table 2). The  
209 prevalence of NTDs was lower in the two least deprived SIMD quintiles compared to other  
210 quintiles (8.6 [95% CI 7.4, 9.9] and 8.5 [95% CI 7.3, 9.9] per 10,000 total births in quintiles 4  
211 and 5 respectively) (Table 2). Similar patterns were seen for spina bifida and NTDs without  
212 an associated genetic condition, though not for anencephaly (Supplementary Table 2). The  
213 live birth prevalence of NTDs, and of each NTD subtype, was lower in male compared to  
214 female live births (Table 2 and Supplementary Table 2).

215 **NTD time trends and association with sociodemographic factors**

216 Figure 1 shows the observed annual prevalence and unadjusted model estimates for NTDs,  
217 anencephaly, and spina bifida 2000-2021. No time trend (linear or non-linear) was identified  
218 in the prevalence of NTDs (uPRR for year 1.01 [95% CI 0.997, 1.02]  $p=0.16$ ) (Table 3). For  
219 anencephaly, we found evidence of a non-linear time trend: there was no evidence of a  
220 change in prevalence 2000-2012 (uPRR 1.01 [95% CI 0.98, 1.04]  $p=0.64$ ), then evidence of an  
221 increase 2013-2021 (uPRR 1.12 [95% CI 1.06, 1.19]  $p<0.001$ ) (Supplementary Table 3). No  
222 time trend was identified in the prevalence of spina bifida (uPRR 0.99 [95% CI 0.98, 1.01]  
223  $p=0.35$ ) (Supplementary Table 4) or NTDs without an associated genetic condition  
224 (Supplementary Figure 1 and Supplementary Table 5).

225 Table 3 shows associations between maternal age and deprivation and the prevalence of  
226 NTDs. There was evidence that mothers aged 30-34 and 35-39 years old had lower aPRRs  
227 compared to those aged 25-29 years when adjusted for both maternal deprivation and year.  
228 There was no evidence of differences in aPRRs comparing each SIMD quintile to the least  
229 deprived quintile when adjusted for maternal age and year.

230 The time trend in the prevalence of NTDs did not change after adjusting for maternal age  
231 and deprivation in multivariable models (aPRR for year 1.01 [95% CI 0.999, 1.02]  $p=0.09$ ).

### 232 **Validation of SLiCCD**

233 Table 4 shows the number of babies with an NTD recorded in SLiCCD and/or CARDRISS in  
234 2021. 47 of the 48 babies recorded in SLiCCD with an NTD were confirmed in CARDRISS as  
235 having an NTD, giving a PPV of 98% [95% CI 89, 100]. Of the 69 babies with an NTD recorded  
236 in CARDRISS, 47 were recorded as having an NTD in SLiCCD, giving a sensitivity of 68% [95%  
237 CI 56, 79]. Of the 22 babies that were not recorded as having an NTD in SLiCCD, 20 were  
238 included in SLiCCD in some capacity, with 12 allocated to the Nervous system condition

239 group, but no Neural tube defect subgroup. 19 of the 22 babies had termination of  
240 pregnancy as their pregnancy outcome. PPV and sensitivity of SLiCCD compared to  
241 CARDRISS was similar for all subtypes of NTDs (Supplementary Tables 6-8).

#### 242 **Power to detect a 20% reduction in the total birth prevalence of NTDs**

243 For 2021, the prevalence of NTDs estimated from CARDRISS was 14.3 [95% CI 11.1, 18.1] per  
244 10,000 total births. Based on this, seven years of cumulative data after full implementation  
245 of mandatory fortification will be required to reliably (i.e., with power of at least 80%) detect  
246 a 20% reduction in the prevalence of NTDs (Supplementary Table 9).

247

#### 248 **Discussion:**

249 Our national, population-based study found no evidence of a change in the total birth  
250 prevalence of NTDs in Scotland 2000-2021. We also found no evidence of a change in the  
251 prevalence of spina bifida, or NTDs without an associated genetic condition, over this  
252 period. For anencephaly, there was no change 2000-2012, then a 12% average annual  
253 increase in prevalence 2013-2021. We found that the prevalence of NTDs was lower among  
254 babies to mothers aged 30-39 years (compared to younger or older) and to mothers from  
255 less (compared to more) deprived areas. The finding for maternal age persisted in  
256 multivariable analyses, however adjusting for maternal age and deprivation did not change  
257 our findings relating to trends over time.

258 Our study had strengths and limitations. We provide national, population-based data for a  
259 22-year period with consistent policy on NTD prevention (voluntary fortification of some  
260 foods and daily folic acid supplements). We estimate the associations between NTD

261 prevalence and maternal age and deprivation, and time trends in NTD prevalence, both  
262 unadjusted and adjusted for these key sociodemographic factors.

263 We used a consistent data source (SLiCCD) and validate the most recent year's data against  
264 Scotland's new, validated congenital condition register (CARDRISS) for transparency. The high  
265 PPV of SLiCCD compared to CARDRISS suggests we can have high confidence that babies  
266 included in our analysis were correctly categorised as having an NTD. There are known  
267 limitations in the clinical coding on source national datasets relating to terminations of  
268 pregnancy, leading to under-ascertainment of babies with an NTD and this pregnancy  
269 outcome in SLiCCD compared to CARDRISS. The total birth prevalence of NTDs based on  
270 SLiCCD data that we report is therefore likely to be an underestimate of the true prevalence.  
271 However, as there is no evidence of any change in the quality of termination data over time,  
272 the trends we observe, and our overall interpretation of results, are likely to be valid.

273 Our results align with a recent study assessing trends in the prevalence of NTDs in England  
274 2000-2019(24). While this study found evidence of a small increase in the prevalence of  
275 NTDs over the study period, this was explained by an increase in anencephaly 2015-2019.  
276 We also found an increase in anencephaly over the similar period 2013-2021. Our results  
277 also align with those from an earlier study which found no change in the prevalence of NTDs  
278 without an associated genetic condition in Europe 2003-2011, using data from 28 EUROCAT  
279 registries in 19 European countries, including Wales and parts of England(25).

280 The prevalence of the different subtypes of NTDs would be expected to show similar trends  
281 over time(24,25), hence the recent increase in prevalence of anencephaly, but not spina  
282 bifida, seen in our results (and in England) is surprising. We cannot exclude that the increase  
283 in anencephaly is real (particularly given evidence that population folate status has

284 worsened 2008-2019, the most recent period for which data is available(9)), or due to  
285 changes in data quality. However, given the high spontaneous loss rate of pregnancies  
286 affected by anencephaly, we suggest the most likely explanation is increasing ascertainment  
287 of affected babies in early pregnancy followed by termination of a (diagnosed) pregnancy  
288 rather than miscarriage of an (undiagnosed) pregnancy. Policy interventions from the early  
289 2010s have promoted booking for antenatal care at earlier gestations, and a change in the  
290 method of pregnancy screening for Down's syndrome from second trimester serum  
291 screening to first trimester combined screening, implemented in Scotland from 2011, has  
292 also promoted earlier ultrasound scanning(26,27).

293 We found differences in the prevalence of NTDs by sociodemographic factors, in particular  
294 maternal age. There is evidence of marked inequalities in the uptake of pre-conception folic  
295 acid supplements, with uptake particularly poor in younger women(28), and this may partly  
296 explain our findings. Mandatory fortification offers an opportunity to more effectively and  
297 equitably reduce the prevalence of NTDs, compared to the policy of voluntary fortification  
298 and supplements in place during our study period, although there is debate over whether  
299 the planned scope and level of fortification is sufficient(23,29).

300 Overall, this study shows that the prevalence of NTDs in Scotland 2000-2021 showed no  
301 change, and inequalities in prevalence by maternal age were evident. This study will be used  
302 to inform the evaluation of mandatory folic acid fortification of non-wholemeal wheat flour  
303 in the UK, and hence to guide future public health policy in this and other settings.

304 **Data availability statement**

305 Subject to governance approvals, researchers can access pseudonymised extracts of datasets  
306 used in this study through the Scottish NHS safe haven facility supported by Public Health  
307 Scotland. Interested researchers should submit an initial enquiry form to Research Data  
308 Scotland (<https://www.researchdata.scot/accessing-data/>).

309 **Ethics Statements**

310 **Patient consent for publication**

311 Not applicable

312 **Ethics approval**

313 This study involved the secondary analysis of routinely collected data and approval by an  
314 ethics committee was not required as informed by the NHS Health Research Authority and  
315 Public Health Scotland research risk assessment checklists. A Data Protection Impact  
316 Assessment for this study was approved by the PHS Data Protection Officer (DP22230101).

317 **Acknowledgements**

318 We acknowledge the contribution of the CARDRISS analyst team within Public Health  
319 Scotland in providing relevant data extracts.

320 We acknowledge the contribution of our stakeholder group, including representatives from  
321 Scottish Government, Food Standards Scotland, the NHS Scotland paediatric neurosurgery  
322 service, and Spina Bifida Hydrocephalus Scotland, to study design and interpretation. The  
323 study team had final responsibility for study methodology and interpretation of results.

324 **Contributions**



325 AK, RV, CC, and RW designed the study. AK, RV, CC, and EG conducted the analyses. AK  
326 drafted the manuscript, and all authors reviewed and contributed to its writing. All authors  
327 had access to the data.

328 **Funding**

329 The authors have not declared a specific grant for this research from any funding agency in  
330 the public, commercial, or not-for-profit sectors.

331 **Completing interests**

332 None declared.

### 333 **References**

- 334 (1) Stevenson RE. Brain and spinal cord. In: Stevenson RE, Hall JG, Everman DB, Solomon BD,  
335 editors. Oxford Monographs on Medical Genetics: Human Malformations and Related  
336 Anomalies. Third edition. Oxford: Oxford University Press; 2016. p. 385–402.
- 337 (2) Wald N, Law M, Morris J, Wald D. Quantifying the effect of folic acid. The Lancet (British  
338 edition) 2001 Dec 15;358(9298):2069–2073.
- 339 (3) Prevention of neural tube defects: results of the Medical Research Council Vitamin  
340 Study. MRC Vitamin Study Research Group. Lancet 1991 Ju;338(8760):131–137.
- 341 (4) Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by  
342 periconceptional vitamin supplementation. New England Journal of Medicine 1992 Dec  
343 24;327(26):1832–1835.
- 344 (5) Murphy M, Whiteman D, Stone D, Botting B, Schorah C, Wild J. Dietary folate and the  
345 prevalence of neural tube defects in the British Isles: the past two decades. BJOG : an  
346 international journal of obstetrics and gynaecology 2000 Ju;107(7):885–889.
- 347 (6) Busby A, Abramsky L, Dolk H, Armstrong B. Preventing neural tube defects in Europe:  
348 population based study. BMJ 2005 Mar 12;330(7491):574–575.
- 349 (7) Bestwick JP, Huttly WJ, Morris JK, Wald NJ. Prevention of Neural Tube Defects: A Cross-  
350 Sectional Study of the Uptake of Folic Acid Supplementation in Nearly Half a Million Women.  
351 PLoS ONE 2014 Feb 19;9(2):e89354.
- 352 (8) Shi Y, De Groh M, MacFarlane AJ. Socio-demographic and lifestyle factors associated with  
353 folate status among non-supplement-consuming Canadian women of childbearing age. Can J  
354 Public Health 2014 May 9;105(3):166.
- 355 (9) Public Health England. NDNS: results from years 9 to 11 (2016 to 2017 and 2018 to  
356 2019). 2020; Available at: [https://www.gov.uk/government/statistics/ndns-results-from-](https://www.gov.uk/government/statistics/ndns-results-from-years-9-to-11-2016-to-2017-and-2018-to-2019)  
357 [years-9-to-11-2016-to-2017-and-2018-to-2019](https://www.gov.uk/government/statistics/ndns-results-from-years-9-to-11-2016-to-2017-and-2018-to-2019).
- 358 (10) Crider KS, Qi YP, Yeung LF, Mai CT, Zauche LH, Wang A, et al. Folic Acid and the  
359 Prevention of Birth Defects: 30 Years of Opportunity and Controversies. ANNUAL REVIEW OF  
360 NUTRITION 2022;42:423–452.
- 361 (11) UK government. The Bread and Flour (Amendment) (England) Regulations 2024. 2024;  
362 Available at: <https://www.legislation.gov.uk/uksi/2024/1162/made>. Accessed Nov 21, 2024.
- 363 (12) Mayer C, Craig L, Horgan G. Stochastic modelling to estimate the potential impact of  
364 fortification of flour with folic acid in the UK. Food Standards Scotland 2017 Jul 31.

- 365 (13) von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al.  
366 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:  
367 guidelines for reporting observational studies. *BMJ* 2007 Oct 20;335(7624):806–808.
- 368 (14) Information Services Division Scotland. Congenital anomalies in Scotland: 2012-2017.  
369 2019; Available at:  
370 <https://webarchive.nrscotland.gov.uk/20231129160814/https://www.isdscotland.org/Health-Topics/Maternity-and-Births/Publications/>. Accessed Oct 16, 2024.  
371
- 372 (15) Public Health Scotland. Congenital conditions in Scotland: 2000 to 2021. 2023; Available  
373 at: <https://publichealthscotland.scot/publications/congenital-conditions-in-scotland/congenital-conditions-in-scotland-2000-to-2021/>. Accessed Oct 16, 2024.  
374
- 375 (16) EUROCAT. Guidelines for data registration. Available at: [https://eu-rd-  
376 platform.jrc.ec.europa.eu/eurocat/data-collection/guidelines-for-data-registration\\_en](https://eu-rd-platform.jrc.ec.europa.eu/eurocat/data-collection/guidelines-for-data-registration_en).  
377 Accessed Aug 4, 2024.
- 378 (17) MBRRACE-UK. MBRRACE-UK: Mothers and Babies: Reducing Risk through Audits and  
379 Confidential Enquiries across the UK. Available at: <https://www.npeu.ox.ac.uk/mbrrace-uk>.  
380 Accessed Nov 21, 2024.
- 381 (18) The Scottish Government. Scottish Index of Multiple Deprivation 2020. Available at:  
382 <https://www.gov.scot/collections/scottish-index-of-multiple-deprivation-2020/>. Accessed  
383 Oct 16, 2024.
- 384 (19) National datasets: Scottish Linked Congenital Conditions Dataset (SLiCCD). Available at:  
385 [https://publichealthscotland.scot/services/national-data-catalogue/national-datasets/a-to-  
386 z-of-datasets/scottish-linked-congenital-conditions-dataset-sliccd/](https://publichealthscotland.scot/services/national-data-catalogue/national-datasets/a-to-z-of-datasets/scottish-linked-congenital-conditions-dataset-sliccd/). Accessed 01 Ma, 2024.
- 387 (20) PHS. Congenital Conditions and Rare Diseases Registration and Information Service for  
388 Scotland (CARDRISS). Available at: [https://publichealthscotland.scot/our-areas-of-  
389 work/disease-registration-and-screening/disease-registration/congenital-conditions-and-  
390 rare-diseases-registration-and-information-service-for-scotland-cardriss/overview/](https://publichealthscotland.scot/our-areas-of-work/disease-registration-and-screening/disease-registration/congenital-conditions-and-rare-diseases-registration-and-information-service-for-scotland-cardriss/overview/).
- 391 (21) Mason CA, Kirby RS, Sever LE, Langlois PH. Prevalence is the preferred measure of  
392 frequency of birth defects. *Birth Defects Res A Clin Mol Teratol* 2005 Oc;73(10):690–692.
- 393 (22) Au KS, Ashley-Koch A, Northrup H. Epidemiologic and genetic aspects of spina bifida  
394 and other neural tube defects. *Developmental Disabilities Research Reviews* 2010;16(1):6–  
395 15.
- 396 (23) Morris JK, Addor M, Ballardini E, Barisic I, Barrachina-Bonet L, Braz P, et al. Prevention  
397 of Neural Tube Defects in Europe: A Public Health Failure. *Front Pediatr* 2021 Jun  
398 24;9:647038.
- 399 (24) Broughan JM, Martin D, Higgins T, Swan G, Cullum A, Kurinczuk JJ, et al. Prevalence of  
400 neural tube defects in England prior to the mandatory fortification of non-wholemeal wheat

401 flour with folic acid: a population-based cohort study. Archives of disease in childhood 2024  
402 Fe;109:106–112.

403 (25) Khoshnood B, Loane M, de Walle H, Arriola L, Addor M, Barisic I, et al. Long term trends  
404 in prevalence of neural tube defects in Europe: population based study. BMJ 2015 Nov  
405 24;351:h5949.

406 (26) Scottish Government. NHS Scotland performance against LDP standards. 2022;  
407 Available at: <https://www.gov.scot/publications/nhsscotland-performance-against-ldp-standards/pages/early-access-to-antenatal-services/>. Accessed Nov 21, 2024.

409 (27) Scottish Government. Changes to the pregnancy and newborn screening programmes.  
410 2008; Available at: <https://www.publications.scot.nhs.uk/files/cel2008-31.pdf>.

411 (28) Health and Social Care Information Centre, IFF Research. Infant Feeding Survey - UK,  
412 2010. 2012 Nov 20.

413 (29) Wald N. Folic acid fortification: will the new UK government pass the “acid test”? BMJ  
414 2024;385:q1286.

415

416

Table 1: Number of babies with, and birth prevalence of, neural tube defects (NTDs), Scotland 2000-2021, by NTD sub-type and pregnancy outcome

	Number (%) of babies with a recorded NTD	Number of total ( <i>or live</i> ) births	Total* ( <i>or live</i> †) birth prevalence per 10,000 total ( <i>live</i> ) births (95% CI)
All NTDs	1,178	1,203,491	9.8 (9.2, 10.4)
Live birth	414 (35%)	1,197,700	3.5 (3.1, 3.8)
Stillbirth (≥20 weeks)	49 (4%)		
Termination of pregnancy	715 (61%)		
Anencephaly	436	1,203,491	3.6 (3.3, 4.0)
Live birth	33 (8%)	1,197,700	0.3 (0.2, 0.4)
Stillbirth (≥20 weeks)	32 (7%)		
Termination of pregnancy	371 (85%)		
Encephalocele	165	1,203,491	1.4 (1.2, 1.6)
Live birth	74 (45%)	1,197,700	0.6 (0.5, 0.8)
Stillbirth (≥20 weeks)	4 (2%)		
Termination of pregnancy	87 (53%)		
Spina bifida	577	1,203,491	4.8 (4.4, 5.2)
Live birth	307 (53%)	1,197,700	2.6 (2.3, 2.9)
Stillbirth (≥20 weeks)	13 (2%)		
Termination of pregnancy	257 (45%)		

\*The total birth prevalence is calculated as the total number of babies with a recorded NTD divided by the total number of births (live and stillbirths)

†The live birth prevalence is calculated as the total number of liveborn babies with a recorded NTD divided by the total number of live births

Table 2: Number of babies with, and birth prevalence of, neural tube defects (NTDs), Scotland 2000-2021, by sociodemographic characteristics

	Number (%) of babies ( <i>or live births</i> ) with a recorded NTD	Number (%) of total ( <i>or live</i> ) births	Total* ( <i>or live †</i> ) birth prevalence per 10,000 total ( <i>live</i> ) births (95% CI)
<b>Maternal age (years)</b>			
<20	72 (6%)	69,567 (6%)	10.3 (8.1, 13.0)
20-24	242 (21%)	202,009 (17%)	12.0 (10.5, 13.6)
25-29	345 (29%)	318,696 (26%)	10.8 (9.7, 12.0)
30-34	312 (26%)	362,920 (30%)	8.6 (7.7, 9.6)
35-39	151 (13%)	202,487 (17%)	7.5 (6.3, 8.7)
≥40	50 (4%)	43,189 (4%)	11.6 (8.6, 15.3)
Unknown <sup>‡</sup>	6 (1%)	4,623 (<1%)	-
<b>Maternal deprivation status</b>			
SIMD quintile 1 - most deprived	316 (27%)	300,661 (25%)	10.5 (9.4, 11.7)
SIMD quintile 2	261 (22%)	247,983 (21%)	10.5 (9.3, 11.9)
SIMD quintile 3	228 (19%)	223,307 (19%)	10.2 (8.9, 11.6)
SIMD quintile 4	192 (16%)	223,729 (19%)	8.6 (7.4, 9.9)
SIMD quintile 5 - least deprived	175 (15%)	205,286 (17%)	8.5 (7.3, 9.9)
Unknown <sup>‡</sup>	6 (1%)	2,525 (<1%)	-
<b>Infant sex<sup>§</sup></b>			
<i>Male</i>	<i>203 (49%)</i>	<i>614,369 (51%)</i>	<i>3.3 (2.9, 3.8)</i>
<i>Female</i>	<i>211 (51%)</i>	<i>583,310 (49%)</i>	<i>3.6 (3.1, 4.1)</i>
<i>Unknown<sup>‡</sup></i>	<i>0</i>	<i>21 (&lt;1%)</i>	-

\*The total birth prevalence is calculated as the total number of babies with a recorded NTD divided by the total number of births (live and stillbirths)

†The live birth prevalence is calculated as the total number of liveborn babies with a recorded NTD divided by the total number of live births

‡Total or livebirth prevalence was not calculated for groups with missing sociodemographic data as it would be misleading if patterns of missingness differed in the numerator and (unlinked) denominator data

§Information on infant sex is shown for live births only as sex is often unknown for babies with an NTD where the pregnancy ended in early stillbirth or termination of pregnancy

Table 3: Prevalence rate ratios (PRRs) for neural tube defects (NTDs), Scotland 2000-2021

	Unadjusted PRR (95% CI)	p value	Model 1*		Model 2†		Model 3‡	
			Adjusted PRR (95% CI)	p value	Adjusted PRR (95% CI)	p value	Adjusted PRR (95% CI)	p value
<b>Maternal age (years)</b>								
<20	0.96 (0.75, 1.24)	0.76	0.98 (0.76, 1.26)	0.86			0.97 (0.75, 1.25)	0.81
20-24	1.11 (0.94, 1.30)	0.22	1.11 (0.94, 1.31)	0.20			1.11 (0.94, 1.31)	0.23
25-29	(ref)		(ref)				(ref)	
30-34	0.79 (0.68, 0.93)	<b>0.003</b>	0.79 (0.68, 0.93)	<b>0.003</b>			0.81 (0.69, 0.95)	<b>0.01</b>
35-39	0.69 (0.57, 0.84)	<b>&lt;0.001</b>	0.69 (0.57, 0.83)	<b>&lt;0.001</b>			0.71 (0.58, 0.86)	<b>&lt;0.001</b>
≥40	1.08 (0.80, 1.45)	0.62	1.07 (0.80, 1.44)	0.64			1.11 (0.82, 1.49)	0.51
<b>Maternal deprivation status</b>								
SIMD quintile 1 - most deprived	1.23 (1.02, 1.48)	<b>0.03</b>			1.23 (1.02, 1.48)	<b>0.03</b>	1.10 (0.91, 1.34)	0.31
SIMD quintile 2	1.23 (1.02, 1.49)	<b>0.03</b>			1.23 (1.02, 1.49)	<b>0.03</b>	1.12 (0.92, 1.36)	0.25
SIMD quintile 3	1.20 (0.98, 1.46)	0.07			1.20 (0.98, 1.46)	0.08	1.12 (0.92, 1.37)	0.25
SIMD quintile 4	1.01 (0.82, 1.23)	0.95			1.00 (0.82, 1.23)	0.97	0.96 (0.78, 1.18)	0.72
SIMD quintile 5 - least deprived	(ref)				(ref)		(ref)	
<b>Year (2000 to 2021)</b>								
Average annual change	1.01 (0.997, 1.02)	0.16	1.01 (0.998, 1.02)	0.12	1.01 (0.998, 1.02)	0.12	1.01 (0.999, 1.02)	0.09

PRR: Prevalence Rate Ratio; CI: Confidence Interval; SIMD: Scottish Index of Multiple Deprivation

\*Model 1 is a multivariable model including maternal age and year

†Model 2 is a multivariable model including maternal deprivation status and year

‡Model 3 is a multivariable model including maternal age, maternal deprivation status, and year

Models 1-3 assume the trend of total birth prevalence of NTDs over time is linear

Table 4: Babies recorded as having an NTD in SLiCCD and the CARDRISS register, Scotland 2021

		CARDRISS register		
		Recorded as NTD	Not recorded as NTD	Total
SLiCCD	Recorded as NTD	47	1	48
	Not recorded as NTD	22		
	Total	69		

CARDRISS: Congenital conditions and rare diseases registration and information service for Scotland  
 SLiCCD: Scottish linked congenital condition dataset



It is made available under a [CC-BY 4.0 International license](#) .

Figure 1: Observed and model-estimated annual total birth prevalence of all neural tube defects (NTDs), anencephaly and spina bifida, Scotland 2000-2021

